Skip to content
Accessibility help
Search NICE…
Skip to content
Menu
Sign in
Guidance
Standards and indicators
Life sciences
British National Formulary (BNF)
British National Formulary for Children (BNFC)
Clinical Knowledge Summaries (CKS)
About
Home
NICE guidance
In development
In development: Guidance, quality standards and advice
Skip to filters
Skip to results
Published
In consultation
In development
Awaiting development
Topic selection
Filter (1 applied)
Skip to results
Keyword or reference number
Keyword or reference number
Apply filter
Expected publication date
Expected publication date
From date
To date
Apply date filters
Area of interest
Area of interest
COVID-19 (7)
Type
(
1 selected
)
Type
Guidance (392)
NICE advice (1)
Quality standard (11)
Guidance programme
Guidance programme
Clinical guidelines (29)
Diagnostics guidance (7)
Health technology evaluations (17)
Highly specialised technologies guidance (10)
Interventional procedures guidance (21)
Medical technologies guidance (13)
NICE guidelines (32)
Public health guidelines (1)
Technology appraisal guidance (303)
Apply filters
Showing 226 to 250 of 392
Sort by
Title
Date
Apply sorting
Type: Guidance
Remove Type: Guidance filter
Guidance, NICE advice and quality standards in development
Title
Type
Expected publication date
Nivolumab with ipilimumab for untreated unresectable or metastatic urothelial cancer when cisplatin is unsuitable [ID3939]
Technology appraisal guidance
TBC
Nivolumab with ipilimumab for untreated unresectable stage 3 non-small-cell lung cancer [ID6248]
Technology appraisal guidance
TBC
Non-alcoholic fatty liver disease (NAFLD): assessment and management
NICE guideline
TBC
Non-invasive skin closure devices for surgical incisions (MT775)
Medical technologies guidance
TBC
Nusinersen and risdiplam for treating spinal muscular atrophy (review of TA588 and TA755) [ID6195]
Technology appraisal guidance
TBC
NY-ESO-1 T-cells for treating synovial sarcoma ID1286
Technology appraisal guidance
TBC
Obecabtagene autoleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia [ID6347]
Technology appraisal guidance
25 June 2025
Obeticholic acid for treating liver fibrosis in people with steatohepatitis [ID1645]
Technology appraisal guidance
TBC
Odevixibat for treating cholestasis and pruritus in Alagille Syndrome [ID6181]
Technology appraisal guidance
TBC
Olaparib for treating BRCA mutation-positive HER2-negative metastatic breast cancer after chemotherapy (Review of TA762) [ID6336]
Technology appraisal guidance
TBC
Olaparib with cediranib for treating platinum-resistant recurrent ovarian cancer after 1 or 2 therapies [ID4065]
Technology appraisal guidance
TBC
Olipudase alfa for treating Niemann-Pick disease types A and B [ID3913 ]
Highly specialised technology
TBC
Omaveloxolone for treating Friedreich's ataxia in people 16 years and over ID6423
Technology appraisal guidance
13 August 2025
Omburtamab for treating relapsed neuroblastoma [ID1664]
Technology appraisal guidance
TBC
One-piece closed bags for adults with a colostomy: Late Stage Assessment
Health technology evaluation
TBC
Optical Coherence Tomography to guide percutaneous coronary intervention
Interventional procedures guidance
TBC
Oral paclitaxel with encequidar for treating advanced breast cancer [ID5111]
Technology appraisal guidance
TBC
OrganOx metra for liver transplant [ID5116]
Technology appraisal guidance
TBC
Osimertinib for adjuvant treatment of EGFR mutation-positive non-small-cell lung cancer after complete tumour resection (Review of TA761) [ID5120]
Technology appraisal guidance
TBC
Osimertinib for maintenance treatment of EGFR mutation-positive locally advanced unresectable non-small-cell lung cancer after platinum-based chemoradiation [ID6223]
Technology appraisal guidance
20 August 2025
Osimertinib with pemetrexed and platinum-based chemotherapy for untreated EGFR mutation-positive advanced non-small-cell lung cancer [ID6328]
Technology appraisal guidance
TBC
Osteoporosis: risk assessment, treatment, and fragility fracture prevention (update)
NICE guideline
TBC
Overweight and obesity management
NICE guideline
TBC
Oxybutynin hydrochloride for managing neurogenic detrusor overactivity in people 6 years and over with spinal cord injury or spina bifida [ID5089]
Technology appraisal guidance
TBC
Palbociclib with trastuzumab and endocrine therapy for maintenance treatment of hormone-receptor positive, HER2-positive metastatic breast cancer [ID6251]
Technology appraisal guidance
TBC
Previous page
1
…
8
9
Current page
10
11
12
…
16
Page
10
of
16
Next page
Results per page
10
25
50
All
Back to top